SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Paola Giordano, Giuseppe Lassandro, Michele Valente, Angelo Claudio Molinari, Paola Ieranò, Antonio Coppola, Current Management of the Hemophilic Child: A Demanding Interlocutor. Quality of Life and Adequate Cost-Efficacy Analysis, Pediatric Hematology-Oncology, 2014, 140709064602004

    CrossRef

  2. 2
    F. Abbonizio, A. Giampaolo, A. Coppola, R. Arcieri, H. J. Hassan, Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy, Haemophilia, 2014, 20, 4
  3. 3
    J. W. Hay, S. C. Chaugule, G. Young, Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors, Haemophilia, 2013, 19, 5
  4. 4
    Christoph Kannicht, Margareta Ramström, Guido Kohla, Maya Tiemeyer, Elisabeth Casademunt, Olaf Walter, Helena Sandberg, Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII, Thrombosis Research, 2013, 131, 1, 78

    CrossRef

  5. 5
    S. Rangarajan, S. Austin, N. J. Goddard, C. Négrier, E. C. Rodriguez-Merchan, D. Stephensen, T. T. Yee, Consensus recommendations for the use of FEIBA® in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery, Haemophilia, 2013, 19, 2
  6. 6
    Tsu-Chiang Tu, Shin-Nan Cheng, Jye-Daa Chen, Thau-Ming Cham, Mei-Ing Chung, Economic Burden of High-Responding Inhibitors in Patients with Hemophilia A in Taiwan, Yonsei Medical Journal, 2013, 54, 2, 358

    CrossRef

  7. 7
    C. L. Eckhardt, A. S. van Velzen, M. Peters, J. Astermark, P. P. Brons, G. Castaman, M. H. Cnossen, N. Dors, C. Escuriola-Ettingshausen, K. Hamulyak, D. P. Hart, C. R. M. Hay, S. Haya, W. L. van Heerde, C. Hermans, M. Holmstrom, V. Jimenez-Yuste, R. D. Keenan, R. Klamroth, B. A. P. Laros-van Gorkom, F. W. G. Leebeek, R. Liesner, A. Makipernaa, C. Male, E. Mauser-Bunschoten, M. G. Mazzucconi, S. McRae, K. Meijer, M. Mitchell, M. Morfini, M. Nijziel, J. Oldenburg, K. Peerlinck, P. Petrini, H. Platokouki, S. E. Reitter-Pfoertner, E. Santagostino, P. Schinco, F. J. Smiers, B. Siegmund, A. Tagliaferri, T. T. Yee, P. W. Kamphuisen, J. G. van der Bom, K. Fijnvandraat, Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A, Blood, 2013, 122, 11, 1954

    CrossRef

  8. 8
    G. Di Minno, A. Coppola, Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution?, Haemophilia, 2013, 19,
  9. You have free access to this content9
    F. PEYVANDI, R. KLAMROTH, M. CARCAO, A. B. FEDERICI, G. DI MINNO, V. JIMÉNEZ-YUSTE, E. C. RODRIGUEZ MERCHÁN, Management of bleeding disorders in adults, Haemophilia, 2012, 18,
  10. 10
    Elisabeth Casademunt, Kristina Martinelle, Mats Jernberg, Stefan Winge, Maya Tiemeyer, Lothar Biesert, Sigurd Knaub, Olaf Walter, Carola Schröder, The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics, European Journal of Haematology, 2012, 89, 2
  11. 11
    Antonio Coppola, Matteo N. D. Di Minno, Elena Santagostino, Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches, British Journal of Haematology, 2010, 150, 5
  12. 12
    Abha H Athale, Maura Marcucci, Alfonso Iorio, Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B, The Cochrane Library,
  13. 13
    Abha H Athale, Maura Marcucci, Alfonso Iorio, Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B, The Cochrane Library,